Adaptive Biotechnologies Corporation (ADPT)
NASDAQ: ADPT · Real-Time Price · USD
15.96
-0.77 (-4.60%)
Jan 8, 2026, 4:00 PM EST - Market closed
Adaptive Biotechnologies Employees
Adaptive Biotechnologies had 619 employees as of December 31, 2024. The number of employees decreased by 90 or -12.69% compared to the previous year.
Employees
619
Change (1Y)
-90
Growth (1Y)
-12.69%
Revenue / Employee
$408,326
Profits / Employee
-$128,614
Market Cap
2.44B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 619 | -90 | -12.69% |
| Dec 31, 2023 | 709 | -81 | -10.25% |
| Dec 31, 2022 | 790 | -68 | -7.93% |
| Dec 31, 2021 | 858 | 236 | 37.94% |
| Dec 31, 2020 | 622 | 169 | 37.31% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ADPT News
- 2 days ago - Adaptive Biotechnologies spinout raising $15M to develop clinical sequencing tech - GeekWire
- 9 days ago - Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 24 days ago - Adaptive Biotechnologies signs non-exclusive deals with Pfizer worth up to $890 million - Reuters
- 24 days ago - Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer - GlobeNewsWire
- 4 weeks ago - Adaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual Disease - GlobeNewsWire
- 4 weeks ago - Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting - GlobeNewsWire
- 4 weeks ago - Why Is Adaptive Biotechnologies Stock Trading Lower After Natera's Over $400 Million Deal? - Benzinga
- 6 weeks ago - Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual Meeting - GlobeNewsWire